Skip to content

Gross Profit at other companies

JAN
Janus Living JAN
$3.57M+85.6%
Alkermes logo
AlkermesALKS

Segments

By segment

See full
Reportable Segment$277M+25.3%

Other financials

Income statement

See full
Revenue$317.0M+19.2%
Operating income$137.0M+108%
Net income$89.0M+89.4%
EPS (diluted)$0.69+81.6%

Balance sheet

See full
Cash & equivalents$175.0M-53.0%
Total debt$509.0M+37.6%
Total equity-$144.0M+49.5%
Total assets$1.2B-12.9%

Cash flow

See full
Operating cash flow-$9.0M-112%
CapEx$20.0M+300%
Free cash flow-$29.0M-141%

Valuation

See full
Market cap$4.53B+213%
Enterprise value$4.86B+242%
P/E18×
P/S3.5×+2.3×

Profitability

See full
Gross margin81.3%+1.5pp
Operating margin25.8%+23.3pp
Net margin19.4%+18.9pp
FCF margin-14.9%

Returns & leverage

See full
Return on equity-117%
Debt / equity-3.5×
Current ratio0.9×0.0×

Where this comes from

Calculated from Indivior Pharmaceuticals, Inc. ’s reported figures.

The official record: Indivior Pharmaceuticals, Inc. ’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Indivior Pharmaceuticals, Inc. 's gross profit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Indivior Pharmaceuticals, Inc. 's gross profit?
Indivior Pharmaceuticals, Inc. (INDV) reported gross profit of $277M in Q1 2026.
How has Indivior Pharmaceuticals, Inc. 's gross profit changed year-over-year?
Indivior Pharmaceuticals, Inc. 's gross profit increased by 24.8% year-over-year, from $222M to $277M.
What is the long-term trend for Indivior Pharmaceuticals, Inc. 's gross profit?
Over 3 years (2022 to 2025), Indivior Pharmaceuticals, Inc. 's gross profit has grown at a 9.8% compound annual growth rate (CAGR), from $750M to $994M.
What does gross profit mean?
Revenue minus cost of revenue — the profit available to cover operating expenses, representing the company's pricing power and production efficiency.